Expanded Access for KHK2455

Kyowa Kirin

Status

Conditions: Glioblastoma Multiforme

Treatments: Drug: KHK2455

Study type: Expanded Access

Funder types: Other; Industry

Identifiers

NCT04321694

Expanded Access for KHK2455

Details and patient eligibility

About

This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria